Picture of Neuronetics logo

STIM Neuronetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Neuronetics Inc expected to post a loss of 38 cents a share - Earnings Preview

* Neuronetics Inc  STIM.OQ   STIM.O  is expected to show a
rise in
quarterly revenue when it reports  results on March 7. 
    * The Malvern Pennsylvania-based  company is expected to
report  a
12.0% increase in revenue to $16.819 million from $15.02 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. The company's guidance on November 8
2022, for the period ended December 31, was for revenue between
$16.00 million and $17.00 million.
    * ​Refinitiv's mean analyst estimate for Neuronetics Inc is
for a
loss of 38 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neuronetics
Inc
is $9​, above​ its last closing price of $5.22. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.42       -0.42      -0.28     Beat    33.5
 Jun. 30 2022  -0.41       -0.41      -0.39     Beat    5.3
 Mar. 31 2022  -0.40       -0.40      -0.41     Missed  -2.6​
 Dec. 31 2021  -0.31       -0.32      -0.29     Beat    8.2
 ​​Sep.        -0.32       -0.30      -0.31     Missed  -2.6
 30 2021                                                
 Jun. 30 2021  -0.24       -0.24      -0.29     Missed  -20.8​
 Mar. 31 2021  -0.29       -0.31      -0.31     Met     0
 Dec. 31 2020  -0.23       -0.24      -0.19     Beat    21.1
 This summary was machine generated March 3 at 14:46 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Neuronetics

See all news